Placebo News and Research

RSS

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease.

4 Nov 2013

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.

31 Oct 2013

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2014.

31 Oct 2013

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today reported preliminary data from the Company's ongoing extension study of a Phase I/II clinical trial with its lead product Glassia® to treat pediatric patients with a recently diagnosed type 1 diabetes (T1D).

31 Oct 2013

IQWiG completes first health economic evaluation

The German Institute for Quality and Efficiency in Health Care has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the "efficiency frontier method" works and can provide very helpful results.

31 Oct 2013

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.

31 Oct 2013

Once-daily prescription medicine for COPD now available throughout the U.S.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease, is now available to pharmacies throughout the U.S.

30 Oct 2013

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

30 Oct 2013

Researchers identify new drug for treating irritable bowel syndrome with constipation

An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C), based on nonclinical studies, and quantified its effectiveness in pain relief in human trials.

30 Oct 2013

Study investigates link between sedentary behavior and recurrence of colorectal adenomas

Men who spend the most time engaged in sedentary behaviors are at greatest risk for recurrence of colorectal adenomas, benign tumors that are known precursors of colorectal cancers, according to results presented here at the 12th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 27-30.

29 Oct 2013

Pharmalink's Busulipo receives FDA orphan drug designation

Pharmalink AB, a specialty pharma company focused on orphan and niche products, today announces its product Busulipo, a best-in-class conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation (HSCT; also known as bone marrow transplantation), has received orphan drug designation from the US Food and Drug Administration.

29 Oct 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Regular cannabis users have increased levels of impulsive behaviour, reveals research

New cocaine and cannabis research reveals that regular cannabis users have increased levels of impulsive behaviour. It had previously been argued that this increased impulsivity after cannabis administration was only experienced by occasional users, but that regular users were no longer affected in this way.

29 Oct 2013

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Incyte Corporation (Nasdaq: INCY) announced results from a 12-week, placebo-controlled, dose-escalationin involving 60 patients with active rheumatoid arthritis for its proprietary oral JAK1 inhibitor.

29 Oct 2013

Pulmatrix reports positive results from initial PUR0200 Phase IB clinical study in COPD

Pulmatrix today announced the successful completion and positive results of the first part of a two-part Phase IB clinical study in chronic obstructive pulmonary disease (COPD) patients with their lead clinical candidate PUR0200.

29 Oct 2013

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Biogen Idec Inc. today reported third quarter 2013 total revenues of $1.8 billion, an increase of 32% over the third quarter of 2012. Non-GAAP diluted EPS for the third quarter of 2013 were $2.35, an increase of 23% over the third quarter of 2012.

28 Oct 2013

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Delaying treatment for rheumatoid arthritis could greatly increase the likelihood that patients will suffer joint damage and experience disability two years out, according to a new study from Vivian Bykerk, M.D. at Hospital for Special Surgery. The research will be presented at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals on October 28 in San Diego.

28 Oct 2013

Apremilast drug shows promise for Behcet's ulcers

Apremilast, an orally available small molecule modulating several inflammatory pathways, which is pending approval by the United States Food and Drug Administration, is showing promise in the treatment of mouth and genital ulcers in people with Behcet's syndrome, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in San Diego.

28 Oct 2013

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis who receive early, aggressive therapy with a combination of medications achieve clinical inactive disease status faster than they would with less aggressive therapy, according to new research presented this week at the American College of Rheumatology Annual Meeting in San Diego.

28 Oct 2013

Scientists develop new drug to treat obstructive airway diseases

Scientists have developed a new drug (RPL554) that could treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease in two ways at once, according to new research published in The Lancet Respiratory Medicine.

25 Oct 2013

Placebo News and Research

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Array BioPharma reports net loss of $0.13 per share for first quarter of fiscal 2014

Kamada announces new data from Glassia Phase I/II study in pediatric patients with type 1 diabetes

IQWiG completes first health economic evaluation

CytoDyn submits protocol to FDA for Phase IIb clinical trial of PRO 140

Once-daily prescription medicine for COPD now available throughout the U.S.

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Researchers identify new drug for treating irritable bowel syndrome with constipation

Study investigates link between sedentary behavior and recurrence of colorectal adenomas

Pharmalink's Busulipo receives FDA orphan drug designation

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Regular cannabis users have increased levels of impulsive behaviour, reveals research

Incyte announces results of Phase II clinical trial of oral JAK1 inhibitor in patients with RA

Pulmatrix reports positive results from initial PUR0200 Phase IB clinical study in COPD

Biogen Idec Q3 total revenues increase 32% to $1.8 billion

Delaying rheumatoid arthritis treatment could greatly increase likelihood of joint damage

Apremilast drug shows promise for Behcet's ulcers

Two aggressive therapy approaches effective for children with juvenile idiopathic arthritis

Scientists develop new drug to treat obstructive airway diseases

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News